Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Jianchun Xiao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6976-2423; OpenAlex author ID A5047161742. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 11

  1. TRDMT1-mediated mRNA m5C methylation decreases chemotherapy sensitivity by activating homologous recombination-mediated DNA damage repair and IRS2 expression i… Co-author DOI 10.1016/j.canlet.2026.218725↗
  2. SPP1+ Venous Endothelial Cells and CRABP2+ Tumor Cells Contribute to Favorable Body and Tail Pancreatic Ductal Adenocarcinoma Tumor Microenvironment. Co-author DOI 10.1002/mc.23936↗
  3. CALB2 drives pancreatic cancer metastasis through inflammatory reprogramming of the tumor microenvironment. Co-author DOI 10.1186/s13046-024-03201-w↗
  4. Human Equilibrative Nucleoside Transporter 1: Novel Biomarker and Prognostic Indicator for Patients with Gemcitabine-Treated Pancreatic Cancer. Co-author DOI 10.2147/cmar.s465098↗
  5. Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic cancer. Co-author DOI 10.1007/s13402-023-00836-3↗
  6. CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s13402-020-00569-7↗
  7. The Role of Mitochondria in the Chemoresistance of Pancreatic Cancer Cells. Co-author DOI 10.3390/cells10030497↗
  8. Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer. Co-author DOI 10.1016/j.canlet.2020.05.003↗
  9. Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.1016/j.canlet.2020.06.011↗
  10. Low hENT1 expression indicates poor prognosis in gemcitabine-treated pancreatic cancer patients Co-author DOI 10.21203/rs.2.17850/v1↗
  11. Human equilibrative nucleoside transporter 1 (hENT1) predicts the Asian patient response to gemcitabine-based chemotherapy in pancreatic cancer. Co-author DOI 10.5754/hge12687↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Taiping Zhang · 10 shared papers, 2013–2025 · strength 1.34
  2. Yueze Liu · 8 shared papers, 2019–2026 · strength 1.23
  3. Lei You · 8 shared papers, 2019–2026 · strength 1.16
  4. Wenhao Luo · 7 shared papers, 2019–2026 · strength 1.10
  5. Jiangdong Qiu · 6 shared papers, 2020–2025 · strength 0.94
  6. Fangyu Zhao · 6 shared papers, 2019–2024 · strength 0.80
  7. Gang Yang · 6 shared papers, 2020–2024 · strength 0.79
  8. Hua Huang · 4 shared papers, 2021–2025 · strength 0.63
  9. Yifan Fu · 3 shared papers, 2024–2026 · strength 0.59
  10. Yupei Zhao · 4 shared papers, 2019–2024 · strength 0.53
  11. Jinxin Tao · 3 shared papers, 2023–2025 · strength 0.52
  12. Zhe Cao · 4 shared papers, 2020–2024 · strength 0.49
  13. Zhe Cao · 2 shared papers, 2025–2026 · strength 0.43
  14. Guangyu Chen · 3 shared papers, 2021–2023 · strength 0.40
  15. Tao Liu · 2 shared papers, 2024–2025 · strength 0.35
  16. Gang Yang · 2 shared papers, 2019–2024 · strength 0.30
  17. Yupei Zhao · 1 shared paper, 2026 · strength 0.24
  18. Yuanyang Wang · 1 shared paper, 2026 · strength 0.24
  19. Jiangdong Qiu · 2 shared papers, 2019–2021 · strength 0.21
  20. Hao Chen · 1 shared paper, 2025 · strength 0.20
  21. Yuanyang Wang · 1 shared paper, 2025 · strength 0.20
  22. Jun Wang · 1 shared paper, 2025 · strength 0.20
  23. Dan Su · 1 shared paper, 2023 · strength 0.17
  24. Bo Ren · 1 shared paper, 2024 · strength 0.16
  25. Dan Su · 1 shared paper, 2024 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.